.Pharmacolibrary.Drugs.ATC.N.N05AX12

Information

Aripiprazole is an atypical antipsychotic medication mainly used in the treatment of schizophrenia, bipolar disorder, and as an adjunct in major depressive disorder. It acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and as an antagonist at 5-HT2A receptors. Aripiprazole is approved and widely used today in many countries.

Pharmacokinetics

Reported pharmacokinetic parameters in healthy adult volunteers after a single oral dose.

References

1. Wang, Y, et al., & Raoufinia, A (2024). Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2-Month Ready-to-Use Long-Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder. Clinical pharmacology in drug development 13(6) 631–643. DOI:10.1002/cpdd.1397 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38602057

2. Wang, X, et al., & Phillips, L (2022). Population Pharmacokinetic Modeling and Exposure-Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia. Clinical pharmacology in drug development 11(2) 150–164. DOI:10.1002/cpdd.1022 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34979059

3. Kubo, M, et al., & Azuma, J (2007). Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug metabolism and pharmacokinetics 22(5) 358–366. DOI:10.2133/dmpk.22.358 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17965519

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)